Hypophosphatemia in people living with HIV: No benefit when switching from TDF to TAF.

Treatment with tenofovir disoproxil fumarate (TDF) has been associated with hypophosphatemia mainly due to injury of the renal proximal tubulus. Studies on the impact of tenfovir alafenamid (TAF) on phosphate homeostasis in PLHIV are limited. Prompted by a patient with phosphate wasting under tenofovir but no other evidence for tubular dysfunction, a retrospective cohort analysis with 102 people living with HIV (PLHIV) revealed that hypophosphatemia remained largely unchanged after switching from TDF to TAF.